Search Result

Results for "

Lysophosphatidic Acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (1) Biochemical Assay Reagents (2) Casein Kinase (2) DNA-PK (2) Liposome (1) LPL Receptor (20) Phosphodiesterase (PDE) (4) PI3K (2) PPAR (1) ROCK (2) STAT (1) TGF-beta/Smad (1) TRP Channel (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (4) Endocrinology (2) Infection (3) Inflammation/Immunology (10) Metabolic Disease (6) Neurological Disease (9)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Phospholipids (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Amino acid Transporter Amino Acid Derivatives Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15706

H2L 5765834	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, LPA₃, and LPA₅, with IC₅₀s of 94, 752, and 463 nM respectively .

HY-137862

*1-Oleoyl lysophosphatidic* acid** 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-107614

*1-Oleoyl lysophosphatidic* acid sodium** 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a LPA receptor activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-150204

ONO-0740556	LPL Receptor	Inflammation/Immunology
ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM .

HY-107501

*(Rac)-1-Oleoyl lysophosphatidic* acid sodium** (Rac)-1-Oleoyl-sn-glycero-3-phosphate sodium; (Rac)-1-Oleoyl-LPA sodium	Others	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid ((Rac)-1-Oleoyl-sn-glycero-3-phosphate) sodium is the racemic isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614) .

HY-109854A

(R)-Lisofylline (R)-Lisophylline	STAT	Metabolic Disease Inflammation/Immunology
(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC₅₀ of 0.6 µM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research .

HY-160173

LPA receptor antagonist-1	LPL Receptor	Others
LPA receptor antagonist-1 (example 52) is an antagonist of lysophosphatidic acid (LPA) receptor. LPA receptor antagonist-1 can be used for kinds of studies .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-107614G

1-Oleoyl lysophosphatidic acid (sodium) 1-Oleoyl-sn-glycero-3-phosphate (sodium); 1-Oleoyl-LPA (sodium)	TGF-beta/Smad	Neurological Disease
1-Oleoyl lysophosphatidic acid sodium (GMP) is a GMP-grade 1-Oleoyl lysophosphatidic acid sodium that can be used as an auxiliary reagent in cell therapy. 1-Oleoyl lysophosphatidic acid sodium can stimulate neuronal differentiation in neural progenitor cells from mice or rats, and it also promotes the differentiation of human adipose-derived mesenchymal stem cells into myofibroblast-like cells in vitro by activating the autocrine TGF-β1-Smad signaling pathway .

HY-W923661

*1-Octadecyl lysophosphatidic* acid** PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA	LPL Receptor	Others
1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-116100A

HA155	Phosphodiesterase (PDE)	Inflammation/Immunology
HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC₅₀ of 5.7 nM .

HY-12812

Autotaxin modulator 1	Phosphodiesterase (PDE)	Neurological Disease Cancer
Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer .

HY-128127

NAEPA	LPL Receptor	Others
NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid (LPA) receptor agonist .

HY-W127502

1-Hexadecylglycero-3-phosphate 1-Hex-GPA	Biochemical Assay Reagents	Others
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-100882

ONO-7300243	LPL Receptor	Cardiovascular Disease
ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 (LPA1) antagonist with an IC₅₀ of 25 nM.

HY-117444

ONO-9780307	LPL Receptor	Cancer
ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM .

HY-159983

GS-2278	LPL Receptor	Inflammation/Immunology
GS-2278 is an LPAR1 (lysophosphatidic acid receptor 1) antagonist with potential for research in idiopathic pulmonary fibrosis (IPF) .

HY-126233

PAT-347	Phosphodiesterase (PDE)	Metabolic Disease
PAT-347 is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀ value of 25 nM for murine LPA₂ subtype .

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective *type 1 lysophosphatidic* acid receptor (LPA1) antagonist with IC₅₀**s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively .

HY-125854

Phosphatidylcholines, egg	Liposome	Metabolic Disease
Phosphatidylcholines, egg is an important part of eukaryotic membranes. Phosphatidylcholines, egg is also a major source of the second messenger Diacylglycerol, Phosphatidic acid, Lysophosphatidic acid, and Arachidonic acid, which can be further metabolized to other signaling molecules .

HY-160616

LPA5 antagonist 3	LPL Receptor	Cardiovascular Disease Neurological Disease
LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis .

HY-114379

AS2717638 1 Publications Verification	LPL Receptor	Inflammation/Immunology
AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 38 nM for hLPA5. AS2717638 also significantly improves PGE₂-, PGF_2α-, and AMPA-induced allodynia .

HY-151392

LPA5 antagonist 2	Others	Neurological Disease Inflammation/Immunology
LPA5 antagonist 2 (compound 65) is a high aqueous solubility LPA5 (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains .

HY-157639A

18:2 Lyso PA sodium	Others	Cardiovascular Disease
18:2 Lyso PA sodium is an unsaturated lysophosphatidic acid (LysoPA), a lipid mediator mainly present in plasma and thought to be involved in the pathogenesis of acute coronary syndrome (ACS). 18:2 Lyso PA sodium significantly correlates with serum autotaxin (ATX) in peripheral arteries .

HY-139853

BMS-986278 1 Publications Verification	LPL Receptor	Others
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases .

HY-W339757

Dioctanoylphosphatidic acid sodium	Others	Cancer
Dioctanoylphosphatidic acid sodium functions as a modulator of phagocyte respiratory burst, acts as a precursor to diacylglycerol and lysophosphatidic acid, and influences the phosphorylation of the mammalian target of rapamycin (mTOR) while enhancing the viability of gallbladder carcinoma cells treated with histone deacetylase inhibitors (HDACIs); it is derived from glycerophospholipid through the action of phospholipase D.

HY-132222

SET2	TRP Channel	Cancer
SET2 is a selective TRPV2 antagonist (IC₅₀=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases .

HY-117779

DBIBB	Apoptosis	Endocrinology
DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system .

HY-123522

PAT-048	Phosphodiesterase (PDE)	Inflammation/Immunology
PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC₅₀ and IC₉₀ of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo .

HY-10108

LY294002 Maximum Cited Publications 792 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis Autophagy	Infection Cancer
LY294002 is a broad-spectrum inhibitor of PI3K with IC₅₀s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC₅₀ of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC₅₀ of 1.4?μM. LY294002 is an apoptosis activator .

HY-100619A

BMS-986020 sodium 5+ Cited Publications AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-100619

BMS-986020 5+ Cited Publications AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-126230A

(Rac)-PAT-494	Others	Cancer
(Rac)-PAT-494 is a type II autotaxin inhibitor with the activity of inhibiting the production of lysophosphatidic acid (LPA) in the blood. (Rac)-PAT-494 can participate in the inhibition of diseases related to cancer, fibrosis and inflammation by antagonizing the function of autotaxin. (Rac)-PAT-494 shows high activity in biochemical and plasma tests. (Rac)-PAT-494 can reduce plasma LPA levels after oral administration to rats .

HY-139061

Palmitoyl 3-carbacyclic phosphatidic acid	LPL Receptor ROCK	Cancer
Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .

HY-151391

LPA5 antagonist 1	Biochemical Assay Reagents	Neurological Disease
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162596

NRL-1049 BA-1049	ROCK	Neurological Disease
NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC₅₀: 0.59 µM and 26 µM for ROCK2 and ROCK1 respectively). NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice .

HY-10108A

LY294002 hydrochloride Maximum Cited Publications 792 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis	Cancer
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .

Cat. No.	Product Name	Type

HY-107614G

*1-Oleoyl lysophosphatidic* acid (sodium) (GMP)** 1-Oleoyl-sn-glycero-3-phosphate (sodium) (GMP); 1-Oleoyl-LPA (sodium) (GMP)	Fluorescent Dye
1-Oleoyl lysophosphatidic acid sodium (GMP) is a GMP-grade 1-Oleoyl lysophosphatidic acid sodium that can be used as an auxiliary reagent in cell therapy. 1-Oleoyl lysophosphatidic acid sodium can stimulate neuronal differentiation in neural progenitor cells from mice or rats, and it also promotes the differentiation of human adipose-derived mesenchymal stem cells into myofibroblast-like cells in vitro by activating the autocrine TGF-β1-Smad signaling pathway .

1-Oleoyl lysophosphatidic acid (sodium) (GMP)

1-Oleoyl-sn-glycero-3-phosphate (sodium) (GMP); 1-Oleoyl-LPA (sodium) (GMP)

Fluorescent Dye

1-Oleoyl lysophosphatidic acid sodium (GMP) is a GMP-grade 1-Oleoyl lysophosphatidic acid sodium that can be used as an auxiliary reagent in cell therapy. 1-Oleoyl lysophosphatidic acid sodium can stimulate neuronal differentiation in neural progenitor cells from mice or rats, and it also promotes the differentiation of human adipose-derived mesenchymal stem cells into myofibroblast-like cells in vitro by activating the autocrine TGF-β1-Smad signaling pathway .

Cat. No.	Product Name	Type

HY-W127502

1-Hexadecylglycero-3-phosphate 1-Hex-GPA	Cell Assay Reagents
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-107614G

*1-Oleoyl lysophosphatidic* acid (sodium) (GMP)** 1-Oleoyl-sn-glycero-3-phosphate (sodium) (GMP); 1-Oleoyl-LPA (sodium) (GMP)	Biochemical Assay Reagents
1-Oleoyl lysophosphatidic acid sodium (GMP) is a GMP-grade 1-Oleoyl lysophosphatidic acid sodium that can be used as an auxiliary reagent in cell therapy. 1-Oleoyl lysophosphatidic acid sodium can stimulate neuronal differentiation in neural progenitor cells from mice or rats, and it also promotes the differentiation of human adipose-derived mesenchymal stem cells into myofibroblast-like cells in vitro by activating the autocrine TGF-β1-Smad signaling pathway .

1-Oleoyl lysophosphatidic acid (sodium) (GMP)

1-Oleoyl-sn-glycero-3-phosphate (sodium) (GMP); 1-Oleoyl-LPA (sodium) (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P0103

Myristoyl pentapeptide-17	Peptides	Others
Myristoyl pentapeptide-17 can stimulate eyelash growth by stimulating keratin production. Myristoyl pentapeptide-17 promotes the delivery of key ingredients in the serum, such as the growth factors and lysophosphatidic acid .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83630

	EDG2 Antibody (YA3375) Lysophosphatidic Acid receptor 1; LPA receptor 1; LPA-1; Lysophosphatidic Acid receptor Edg-2; LPAR1; EDG2; LPA1	WB, IHC-P, IP	Human
	EDG2 Antibody (YA3375) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3375), targeting EDG2, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). EDG2 Antibody (YA3375) can be used for WB, IHC-P, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-125854

Phosphatidylcholines, egg		Phospholipids
Phosphatidylcholines, egg is an important part of eukaryotic membranes. Phosphatidylcholines, egg is also a major source of the second messenger Diacylglycerol, Phosphatidic acid, Lysophosphatidic acid, and Arachidonic acid, which can be further metabolized to other signaling molecules .

HY-157693

C18:1 Cyclic LPA		Phospholipids
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: